By understanding the pathogenesis of chronic graft-versus-host disease (GvHD), treatments can be better targeted to improve patient outcomes. In this video, Steven Pavletic, MD, MS, from the National Cancer Institute, Bethesda, MD, talks about targeting T-cell, B-cell and APC activation to treat chronic GvHD, in order to derive alternative therapies to corticosteroid treatment. Dr Pavletic was speaking from the European Society for Blood and Marrow Transplantation (EBMT) 2018 Annual Meeting, held in Lisbon, Portugal.
Targeting T-cell, B-cell & APC activation to treat chronic GvHD
